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Jeffamine ED-600 (Pubchem CID: 16212614)In the current study, biodegradable PHBV/PLGA blend nanoparticles (NPs) containing Teriparatide were loaded
in hyaluronic acid/jeffamine (HA-JEF ED-600) hydrogel to prepare a combination delivery system (CDS) for
prolonged delivery of Teriparatide. The principal purpose of the present study was to formulate an effective
and prolonged Teriparatide delivery system in order to reduce the frequency of injection and thus enhance pa-
tient's compliance. Morphological properties, swelling behaviour, crosslinking efﬁciency and rheological charac-
terization ofHA-JEF ED-600 hydrogelwere evaluated. The CDSwas acquired by adding PHBV/PLGANPs toHA-JEF
ED-600 hydrogel simultaneously with crosslinking reaction. The percentage of NPs incorporation within the hy-
drogel as well as the loading capacity andmorphology of Teriparatide loaded CDSwere examined. Intrinsic ﬂuo-
rescence and circular dichroism spectroscopy proved that Teriparatide remains stable after processing. The
release proﬁle represented 63% Teriparatide release from CDSwithin 50 days with lower burst release compared
to NPs and hydrogel. MTT assay was conducted by using NIH3T3 cell line and no sign of reduction in cell viability
was observed. Based on Miller and Tainter method, LD50 of Teriparatide loaded CDS was 131.8 mg/kg. In vivo
studies demonstrated that Teriparatide loaded CDS could effectively increase serum calcium level after subcuta-
neous injection inmice. Favourable results in the current study introduced CDS as a promising candidate for con-
trolled delivery of Teriparatide and pave the way for future investigations in the ﬁeld of designing prolonged
delivery systems for other peptides and proteins.
© 2017 Elsevier B.V. All rights reserved.Keywords:
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Teriparatide1. Introduction
Osteoporosis is a bone thinning disorder characterized by progres-
sive decline in bone mineral density. This skeletal disease is now-hydroxyvalerate acid); PLGA,
mbination delivery system; HA,
ment efﬁciency; LC, loading ca-
echnology Units Incubator, No.
osh).identiﬁed as themost common cause of bone loss particularly in the el-
derly. It is a silent disease because of its symptomless growth until oc-
currence of painful and severe fractures in patients. One in three
women and one in four men aged over 50 will undergo at least one os-
teoporotic fracture and other related complications in their life span
(Willson et al., 2015). Osteoporosis is also responsible for N8.9 million
bone fragilities that occurs annually worldwide (Hernlund et al.,
2013). Due to the universal expansion of osteoporosis, the efﬁcacy and
potency of numerous anti-osteoporotic agents in management of this
skeletal condition have been largely investigated. Bisphosphonates
such as Alendronate, Etidronate, Risedronate and Ibandronate are
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rosis (Ott, 2011). Denosumab, Raloxifene, Calcitonin, Strontium
Ranelate and Teriparatide (recombinant human parathyroid hormone)
[rhPTH (1–34)] are the other recommended therapies (Iwamoto et al.,
2006; Riggs and Parﬁtt, 2005). Among these treatment options,
Teriparatide has unique effects. It is the only FDA approved drug
which triggers bone formation through stimulation of osteoblasts,
whereas the other traditional drugs known as bone resorption inhibi-
tors are able to only inhibit osteoclasts. Teriparatide is an anabolic
agent mainly administrated for patients suffering from glucocorticoid-
induced osteoporosis, postmenopausal osteoporosis and patients who
have failed to response to other anti-osteoporotic agents (Neer et al.,
2001). The recommended therapeutic dose of Teriparatide is 20 μg
injected subcutaneously once a day for two years (Eriksen et al.,
2014). Since most of osteoporotic patients are the elderly, it cannot be
disguised that repeated injection of Teriparatide for a long time is pain-
ful and irritating for the patients and it may even cause medication
withdrawal. Poor patients' acceptance to multiple injections and also
the exclusive properties of Teriparatide in promoting new bone forma-
tion (Eriksen and Robins, 2004) have provoked researchers to work on
development of Teriparatide long acting formulation. Subsequently, the
frequency of injection will be lessened and patient compliance will
improve.
There are only few studies available on Teriparatide sustained re-
lease formulation and its characterization (Eswaramoorthy et al.,
2012;Wei et al., 2004). Since Teriparatide is a bioactive peptide, general
concerns such as high sensitivity and poor stability are the big chal-
lenges to be considered. Despite these facts, various strategies have
been employed to achieve long acting formulation of peptides and pro-
teins consisting of micro (Gaignaux et al., 2012; Geng et al., 2008) and
nanoparticulate delivery systems (Emami et al., 2014; Parajo et al.,
2010), hydrogels (Motokawa et al., 2006) and combination delivery sys-
tem (CDS) (Peng et al., 2013; Hu et al., 2012). Although particulate de-
livery systems are the most widely used carriers in this ﬁeld of drug
delivery, countless efforts in obviating numerous problems accompa-
nied with these systems have led to the break down (Allison, 2008;
Yeo and Park, 2004). Poor encapsulation of peptide and protein, which
results in a suddenburst release and subsequent undesirable adverse ef-
fects, is themost troublesome issuewhich should be resolved for further
successful application of particulate carriers in clinics. Owing to this
issue, various strategies such as blending of different biocompatible
and biodegradable polymers with the aim of fabricating core-shell par-
ticles were employed (Chatterjee et al., 2014; Vukomanovic et al., 2011;
Vukomanovi'ca et al., 2011; Zhu et al., 2009). Unfortunately, even core-
shell nanoparticles (NPs) did not completely show promising results in
enhancing entrapment efﬁciency (EE) and reducing initial burst release
in polymeric particulate systems. In spite of various novel designs in
fabricating more efﬁcient particulate systems, a relatively large amount
of drug still remains un-entrapped on the surface of particles and this
leads to unwanted burst release.
Hydrogels also displayed uncontrolled swift release during the initial
hours after injection (Wireland et al., 2007). Hence neither particulate
systems nor hydrogels provide an ideal controlled release system for
delivery of peptides and proteins. Thus, the new generation of con-
trolled release formulation identiﬁed as CDS, which is the hybrid form
of previously mentioned carriers, has recently come to the world of re-
search. Fabricating a new CDS, keeping desirable properties of both NPs
andhydrogels, is a promisingperspective of the current study to achieve
an ideal controlled release system for delivery of Teriparatide. In other
words, CDS was prepared as a novel prolonged drug delivery system
for subcutaneous injection of Teriparatide in patients suffering from os-
teoporosis to reduce the number of injections and therefore enhance
patient's acceptance.
Among the polymers used in preparation of NPs, Poly (3-
hydroxybutyrate-co-3-hydroxyvalerate acid) (PHBV) is a biocompatible
and biodegradable polymer (Vilos et al., 2012; Lee et al., 2011) whichhas attracted pharmaceutical's attention in recent years due to its
favourable properties in drug delivery and low cost of production
(Vilos et al., 2013). The only obstacle in the extensive use of PHBV is
its poor thermal stabilitywhichwill be signiﬁcantly decreased by blend-
ing this polymer with other polymers like Poly (lactic-co-glycolic acid)
(PLGA) (Bazzo et al., 2012; Huang et al., 2009; EmilioMendes et al.,
2012; Zhu et al., 2009). Besides this, polymer blending was previously
introduced as a beneﬁcial strategy in increasing EE of hydrophilic
drugs into hydrophobic polymers to some extent although it could not
be fully an effective solution (Zhu et al., 2009; Santander-Ortega et al.,
2007; Csaba et al., 2006).
In the present study, PHBV/PLGA blend NPs were loaded in
Hyaluronic acid (HA) based hydrogel as a second barrier in order to at-
tain a desirable controlled release systemwhichwould not only sustain
the peptide release but also diminish the burst release. HA as an impor-
tant ingredient of extracellularmatrix of human body, played amomen-
tous role in cartilage lubrication because of its high capacity for water
absorption whichmakes it an eligible candidate for biomedical applica-
tions and in particular for hydrogel preparation (Ouasti et al., 2011; Oha
et al., 2010; Hahn et al., 2006;Motokawa et al., 2006). Subsequently, the
morphological properties, swelling ratio, cross-linking efﬁciency and
rheological behaviour of HA hydrogel were investigated to characterize
both physical and chemical properties of the fabricated hydrogel.
Teriparatide loaded PHBV/PLGA blend NPs were successfully pre-
pared and optimized according to our recently published work (Bahari
Javan et al., 2016) and thereafter Teriparatide NPs were embedded in
HA based hydrogel simultaneously with crosslinking reaction using
Jeffamine ED-600 (aliphatic diamine derived from a propylene oxide
capped polyethylene glycol) as a cross-linking agent to form CDS. The
constructed CDS in this study resulted in 63% Teriparatide release over
50 days in a more sustained and controlled pattern compared to both
PHBV/PLGA NPs and hydrogels alone. In order to elucidate the in vivo
performance of CDS containing Teriparatide, it was subcutaneously
injected in mice and serum calcium level was determined. Increase in
calcium level was the proof of effective delivery of Teriparatide after
subcutaneous injection.
Pursuant to the desirable properties of NPs and hydrogels, the com-
bination of these two carriers brings us one step closer to achieving a
controlled release formulation for delivery of peptides and proteins.
Thus the current study pays, for the ﬁrst time, particular attention to de-
veloping a novel injectable hyaluronic acid based hydrogel loaded with
Teriparatide-PHBV/PLGA NPs to further prolong the biologic effect of
Teriparatide as a result of which the frequency of injection will be
reduced.
2. Materials and methods
2.1. Materials
PHBV containing 2–3% polyhydroxyvalerate (PHV) by weight was
purchased from Tianan Biologic Materials Ltd., Hangzhou, China;
Teriparatide [rhPTH (1–34)] was obtained from Henan New-Sensation
Chemical Co., Ltd. China. O, O′-Bis (2-aminopropyl) polypropylene
glycol-block-polyethylene glycol-block-polypropylene glycol (Jeffamine
ED-600), PLGA(50:50), polyvinyl alcohol (PVA) (average mol wt.
30,000–70,000), 1-Ethyl-3-[3-(dimethylamino) propyl] carbodiimide
(EDC), N-hydroxysuccinimide (NHS), morpholinoethanesulfonic acid
(MES), ninhydrin and hyaluronidase (HAse) from bovine testes (400–
1000 units/mg) were all purchased from Sigma-Aldrich. All other re-
agents and solvents used in this work were analytical grade and they
were obtained from Merck.
2.2. Synthesis of chemically crosslinked HA based hydrogel
Initially, 200 mg Jeffamine ED-600(JEF ED-600), as a crosslinking
agent, was accurately weighed, dissolved in 4 ml methylene chloride
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JEF ED-600, excess amounts of anhydrous Na2SO4were added to the so-
lution and thereafter it was separated by ﬁltration. The organic solvent
was removed by rotary evaporator and dried at room temperature for
24 h.
After that, 110mgMES and 117mgNaClwere dissolved in 10ml de-
ionized water to prepare an appropriate buffer solution. In order to ob-
tain 1%w/vHA in buffer solution, 40mgHAwas dissolved in 4ml buffer
solution. Then pH was adjusted to 5.5. Afterwards, 174 mg NHS and
580 mg EDC were added to the previously prepared solution to activate
carboxyl groups on the backbone of HA. JEF ED-600 was then added to
HA solution and continuously stirred at room temperature for approxi-
mately 8 h. In the next step, the solution was spread on the Teﬂon plate
and remained at room temperature for 24 h until it completely dried. Fi-
nally, HA-JEF ED-600 hydrogel was gently cut into smaller pieces and
placed in deionized water to remove unreacted reagents for further
assessments.
2.3. Structural characterization of HA-JEF ED-600 hydrogel
The structure of the resulting hydrogel was examined by both Fouri-
er Transformed Infrared Spectroscopy (FTIR, Nicolet Magna IR-550,
Thermo Electron Corporation, Beverly, Massachusetts, USA) and proton
nuclear magnetic resonance (H NMR, 500 MHz, Bruker, Fällanden,
Switzerland).FTIR spectra were acquired from samples in solid form
using KBr as a ﬁller, within 400–4000 cm−1 at room temperature. H
NMR spectra were conducted at room temperature using D2O as a
solvent.
2.4. Degree of swelling ratio
The swelling ratio of both HA-JEF ED-600 hydrogel and CDS (NPs
loaded in HA-JEF ED-600 hydrogel) was determined. Hydrogel and
CDS were separately weighed and placed in phosphate buffer saline
(PBS) at 37 °C for 5 days. At predetermined intervals including 1, 2, 6,
12, 24, 48, 72, 96 and 120 h, the wet samples were removed from PBS
medium through ﬁltration and the weight of swollen carriers were de-
termined. Finally the percentage of swelling ratio was calculated apply-
ing the following formula:
Swelling ratio %ð Þ ¼Ws−Wd=Wd  100 ð1Þ
whereWs is theweight of swollen samples (hydrogel or CDS) andWd is
the weight of dry samples prior to immersing in PBS medium.
2.5. Measurement of crosslinking efﬁciency
The ninhydrin assaywas employed to determine the crosslinking ef-
ﬁciency. Initially, the samples were dispersed in 5 ml of 1 M sodium ac-
etate buffer (pH = 5) and then excessive amount of ninhydrin reagent
was appended to the medium. Thereafter, the mixture was gently
stirred at 85 °C for approximately 25min and the test mediumwas cov-
ered with a piece of parafﬁn ﬁlm to avoid solvent loss. In the next step,
75 ml of water/ethanol (1/1, v/v) was added to the mediumwhich was
then kept in a dark condition and cooled to room temperature in a cold
water bath before measuring the absorbance. The aforementioned pro-
cedure was followed for the material remaining on the ﬁlter as well as
for the unreacted JEF ED-600 collected from the rinse solution. This
was done in order to determine the amount of JEF ED-600 grafted
through one amino group called “single end anchorage” and to quantify
the amount of crosslinking agent which remained intact and unreacted
during coupling reaction, respectively. Ninhydrin reacted with both
unreacted amino groups and single end anchorage of JEF ED-600 and
formed a bluish-red substance whichwas furthermeasured by spectro-
photometer (752S UV/VIS Spectrophotometer, Angstrom Advanced
Inc., Stoughton, Norfolk County, Massachusetts, USA) at thewavelengthof 570 nm. Eventually, the crosslinking efﬁciency (%) wasmeasured ac-
cording to the following equation:
Crosslinking efficiency %ð Þ ¼ ðJEF ED−600initial−ðJEF ED−600single end anchorage
þJEF ED−600unreactedÞ=JEF ED−600initialÞ  100
ð2Þ
where JEF ED-600initial indicates the initial amount of jeffamine added to
themedium at the beginning of reaction, JEF ED-600single end anchorage re-
fers to the amount of jeffamine chemically grafted only through one
amino group and JEF ED-600unreacted states the amount of jeffamine
remained unreacted.
2.6. Rheological characterizations
The rheological behaviour of newly designed HA-JEF ED-600 hydro-
gelwas investigated bymeans of a parallel plate rheometer (Anton Paar,
Physica MCR 301, Styria, Austria) at 25 °C, angle of 1°. Brieﬂy, the sam-
ples were placed on the stationary plate (diameter 15 mm) of rheome-
ter and the rheological experiments were carried out after temperature
equilibrium at 0.01–1000 s−1. Themaximum time spent on performing
each test was 20 min. Additionally, small amplitude oscillatory shear
(SAOS) method was utilized to evaluate the viscoelastic properties of
the fabricated hydrogels including shear storage or elastic modulus (G′)
and shear loss or viscous modulus (G″). The angular frequency sweep
was conducted from 0.05–500 rad/s at 25 °C.
2.7. Preparation of Teriparatide loaded combination delivery system (CDS)
and Teriparatide loaded HA-JEF ED-600 hydrogel
In order to fabricate Teriparatide loaded CDS including Teriparatide-
PHBV/PLGA NPs loaded in HA-JEF ED-600 hydrogel, two individual
steps were carried out. Initially, Teriparatide loaded PHBV/PLGA blend
NPs were prepared via double emulsion solvent evaporation technique
(W1/O/W2) and optimized by using Box-Behnken response surface
methodology, according to our previous work (Bahari Javan et al.,
2016). Thereafter, the optimized Teriparatide-PHBV/PLGA NPs were
embedded in HA-JEF ED-600 hydrogel concurrently to crosslinking re-
action to form Teriparatide loaded CDS. In other words, in the utilized
method for preparation of CDS, the NPs entrapment within the matrix
of hydrogel and the crosslinking occur simultaneously. For this purpose,
after activating carboxylic groups on the backbone of HA via EDC and
NHS, Teriparatide loaded NPs were added to 4 ml HA solution (1% w/
v) under gentle magnetic stirring, accompanied by the addition of
200 mg JEF ED-600. Three different weight ratios of NPs: hydrogel
(1:1, 2:1 and 4:1) were selected to distinguish the optimum ratio.
Thereafter, the percentage of NPs incorporationwithin thematrix of hy-
drogel and loading capacity (%LC) of CDS for each ratio were calculated
according to the following formulas:
%NPs Incorporation ¼WCDS−WHydrogel=WInitial NPs  100 ð3Þ
%LC ¼ WCDS−WHydrogel
 %LE of NPs =WCDS  100 ð4Þ
where WCDS, W Hydrogel and W Initial NPs refer to weight of constructed
CDS, weight of HA- JEF ED-600 hydrogel alone (without NPs) and
weight of initial amount of Teriparatide loadedNPs using in CDS fabrica-
tion, respectively. %LE of NPs alluded to the loading efﬁciency of former-
ly optimized PHBV/PLGA NPs loaded with Teriparatide reported in our
previous work (Bahari Javan et al., 2016).
Teriparatide loaded HA-JEF ED-600 hydrogel was prepared using a
similar method with minor modiﬁcations. Brieﬂy, after activating the
carboxylic groups on the backbone of HA with the aid of EDC and
NHS,765 μg Teriparatide was added to 4 ml HA solution (1% w/v)
under gradual stirring, followed by the addition of 200 mg JEF ED-600
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to the described method in Section 2.2.
2.8. Morphological characterizations
HA-JEF ED-600 hydrogel and CDS containing Teriparatideweremor-
phologically assessed by Field Emission Scanning Electron Microscopy
(FESEM, S4160, Hitachi, Japan). The samples were mounted on the alu-
minium stubs and were coated by a thin layer of gold with a sputter
coater to prevent them from charging.
2.9. In vitro Teriparatide release studies
The release proﬁle of Teriparatide from CDS was investigated and
the acquired results were compared with both previously optimized
PHBV/PLGA NPs and HA-JEF ED-600 hydrogel containing Teriparatide.
In order to measure the initial amount of Teriparatide incorporated in
HA-JEF ED-600 hydrogels, 200 μl of HAse solution (500 units/ml) was
utilized to degrade HA-JEF ED-600 hydrogel at 37 °C in 24 h. Thereafter,
100 μl of the decomposed solutionwas collected and dilutedwith 300 μl
of PBS (pH = 7.4) prior to high performance liquid chromatography
(HPLC, Agilent technology, Santa Clara, California, USA) for quantitative
measurements of Teriparatide (Rane et al., 2012).
In vitro release studies of Teriparatide from both CDS and hydrogel
were conducted using the dialysis method as follows. In order to allow
only the released Teriparatide to permeate into the medium and retain
the polymeric carriers, dialysis bags withmolecular weight cut-off of 12
KD were employed. Initially, the samples (50 mg CDS or hydrogel con-
taining Teriparatide) were dispersed in 1 ml of PBS (pH = 7.4) and
then added to dialysis bag. Thereafter, the dialysis bag was submerged
into 10ml PBSwhich had been pre-heated to 37 °C. The releasemedium
was shaken under mechanical agitation. At predetermined intervals,
100 μl of aliquots were withdrawn and the release medium was
replenished with freshly prepared PBS to maintain the sink condition
during the experiment. In order to testify that the dialysis bag had no
retaining impact on peptide release, the release pattern of free
Teriparatide was also evaluated.
2.10. Mathematical modelling of release data
The kinetic of Teriparatide release from CDS and the mechanism of
release were examined by ﬁtting the data gained from in vitro release
studies to different mathematical models consisting of zero order,
ﬁrst-order, Higuchi's and Korsmeyer's models. For zero and ﬁrst order
models deﬁned as a constant rate and linear kinetic mechanisms,
Eqs. (5) and (6) were used, respectively. The release data was also
analysed by the Higuchi's model (Eq. (7)), as well as Korsmeyer's
model (Eq. (8)).
Mt ¼ K0t ð5Þ
Log Mt ¼ logM0−K1t=2:303 ð6Þ
Mt=M∞ ¼ KHt½ ð7Þ
Mt=M∞ ¼ K0tn ð8Þ
Mt andM0 displays the amount of drug released at time t and the initial
amount of drug released, respectively. Mt/M ∞ is the portion of drug re-
leased. K0, K1 and KH are the rate constants for zero, ﬁrst and Higuchi
models, respectively. K′ is the release rate constant identifying geomet-
ric properties of the carrier and “n” is the diffusion-power that repre-
sents the main mechanism of drug transport.2.11. Stability of Teriparatide
2.11.1. Intrinsic ﬂuorescence spectroscopy
Intrinsic ﬂuorescence spectroscopy was used to conﬁrm that addi-
tion of different excipients and formulation condition processing did
not alter the structure of Teriparatide during CDS preparation. In this
method, the samples were interspersed in deionized water and subse-
quently subjected to spectroﬂuorometer (LS 55, Perkin Elmer,Waltham,
Massachusetts, USA). Intrinsic ﬂuorescence was scanned between 250
and 400 nm. The excitation slits, emission slits, excitation wavelength
and emissionwavelengthwere set at 2.5, 5.0, 295.93 and 360.92 nm, re-
spectively. Additionally, neat Teriparatide was dissolved in deionized
water and investigated by spectroﬂuorometer.
2.11.2. Circular dichroism
The stability of Teriparatide was further proved by circular dichro-
ism (CD) using circular dichroism spectrometer (Model 215, Aviv, Lake-
wood, Los Angeles County, California, USA). A CDS containing 0.5mg/ml
Teriparatide was utilized for Far-UV CD measurements at 180–250 nm
in a 0.02 cm quartz cuvette. The CD signal was the average of ﬁve repli-
cated scans and the corresponding solvent spectrum was subtracted
from the sample spectrum. Pure Teriparatide, as a reference, was also
assessed by circular dichroism spectrometer.
2.12. Cytotoxicity studies
The cytotoxicity of Teriparatide, CDS (drug free) and Teriparatide
loaded CDS against NIH3T3 was evaluated using MTT colorimetric
assay. In this method, the yellow water soluble tetrazolium salt, MTT
(Sigma, Germany), is reduced to purple insoluble formazan crystals.
The formazan crystals are then solubilized using an organic solvent,
such as DMSO, and the optical density of the resultant solution will be
attributed to the number of metabolically active cells.
For this purpose, NIH3T3, the standard ﬁbroblast cell line are obtain-
ed from Iranian Biological Resource Center (IBRC, Tehran, Iran). NIH 3T3
cells aremouse embryonic cell lines of a non-malignant origin. Although
it is immortalized andnot diploid, it is considered to be a normal like cell
line and a suitable, standard model for cytotoxicity assessment in
in vitro experiments (Orsine et al., 2013; Tomankova et al., 2015;
Hillegass et al., 2010).
Cells cultured in RPMI 1640 medium containing 10% FBS, 2 mM L-
glutamine, 100 units/ml penicillin and 100 μg/ml streptomycin (all
from Biosera, UK) in humidiﬁed air with 5% CO2 at 37 °C. Brieﬂy, the
cells were seeded in a 96-well plate at a cell density of 104 cells/well.
24 h later, the cells were treated with four different concentrations of
Teriparatide-CDS (0.05, 0.5, 5 and 50 nM) and their corresponding
CDS alone. To rule out toxicity of Teriparatide per se, the cells were
also treated with the highest concentration of Teriparatide (50 nM).
24 and 48 h after treatment, the medium was removed and 20 μl of
5 mg/ml MTT in PBS was added to each well. Later, the plates were in-
cubated in darkness for 4 h at 37 °C. Then 60 μl of DMSO was appended
to each well to dissolve the water insoluble formazan crystals and then
the plates were vigorously shaken to ensure complete solubilisation.
The intensity of the colour produced in each well was measured by mi-
croplate reader (BioTek ELX800, Winooski, Chittenden County, Ver-
mont, USA) at 570 nm wavelength and a reference wavelength of
690 nm. The reproducibility of the results was ensured by at least
three independent experiments with a minimum of eight internal rep-
licates. The cell viabilitywas calculated according to the following equa-
tion:
Cell viability %ð Þ ¼ Abss=Abscontrolð Þ  100 ð9Þ
where, Abss is the absorption of incubated samples containing CDS/
Teriparatide-CDS and Abscontrol is the absorption of non-treated.
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Animal experiments were carried out in compliancewith guidelines
approved by the Animal Care and Use Committee of Tehran University
of Medical Sciences. The animals were kept under standard laboratory
conditions (temperature 24 °C and 12 h light-dark cycle) for 7 days
prior to the studies to acclimatize to the experimental environment.
Food and tap water was provided ad libitum.
2.13.1. LD50 calculations
LD50 was determined according to Miller and Tainter method
(Randhawa, 2009). The mice fasted for 18 h were injected subcutane-
ously by Teriparatide loaded CDS. Five groups of mice (10 animals in
each group) were injected by ﬁve different doses including 50, 100,
200, 250 and 300 mg/kg. The animals were monitored at 2, 6, 12, 24,
48 and 72 h after administration for any toxic symptoms. After 72 h,
the number of dead mice in each group and the mortality percentage
from 0% to 100% were determined. The percentage of mortality for 0
and 100 were corrected prior to probits measurements. For correction
of 0% and 100% mortality, 100(0.25/n) and 100(n− 0.25/n) formulas
were used, respectively, where n was considered to be 10 mice
(CHANDRA et al., 2014; Randhawa, 2009). Finally, the log-doses were
plotted versus probits. According to Miller and Tainter graphical meth-
od, the dose corresponding to probit 5 stating 50%mortalitywasﬁgured
out as LD50 (Miller and Tainter, 1944).
2.13.2. In vivo Teriparatide bioactivity and efﬁcacy
The mice with free access to water and food were divided into three
groups of 21 mice per group. Group 1, serving as a blank control, was
subcutaneously administrated by blank CDS (PHBV/PLGA NPs loaded
in HA-JEF ED-600 hydrogel, without Teriparatide). Group 2 and 3
were subcutaneously injected by Teriparatide solution in PBS
(0.5 mg/kg) and Teriparatide-CDS (0.5 mg/kg), respectively. At
predetermined time intervals (0, 1, 7, 15, 30, 40 and 50 days), three
mice in each group were anesthetized with an intraperitoneal injection
of ketamine (50 mg/kg) and xylazine (5 mg/kg) and serum calcium
levels were determined by colorimetric assay with o-cresolphthalein
complexonemethod (Cohen and Sideman, 1979). In addition to calcium
determination, CDS was recovered from the injection site at each timeFig. 1. (a) FTIR spectra of (i) HA and (ii) HA-JEF ED-600 hydrogel. (b) H NMR spectra of (i) HA an
amide bonds formation were proved by FTIR and H NMR.point and it was compared in terms of degradation and inﬂammation
to assess the in vivo degradation of CDS (Hahn et al., 2007).3. Results
3.1. Synthesis of HA-JEF ED-600 hydrogel and chemical characterizations
HA carboxyl groups were activated by appending NHS and EDC
using the method explained above. The activated carboxyl groups be-
came ready for covalent crosslinking reaction with amine groups in
JEF ED-600. Eventually, the structure of the newly synthesized hydrogel
was examined by FTIR (Fig. 1a). FTIR spectrum of HA displayed a rela-
tively intense bond at 1664.86 cm−1 corresponding to acetylated
amide groups in the structure of polysaccharide prior to chemical mod-
iﬁcations. The intensity of the aforementioned amide bond in the region
of 1664.86 cm−1 was remarkably enhanced in the FTIR spectrum of HA-
JEF ED-600 hydrogel in comparison with neat HA, which was a
conﬁrmative indicator for formation of new amide bonds. Afterwards,
the structure of HA-JEF ED-600 hydrogel was afﬁrmed by H NMR as
shown in Fig. 1b. According to H NMR spectroscopy, the protons related
tomethyl groups and sugar rings of HA appeared at 1.9 and 3.3 ppm, re-
spectively. After conversion HA to HA-JEF ED-600 hydrogel, the protons
in methyl groups of jeffamine ED-600 became visible at 1 ppm and
slightly below 1 ppm in the H NMR spectrum of HA-JEF ED-600 hydro-
gel. The conjugation percentage revealed fromHNMR area under curve
statistics was found to be 93.9%.3.2. Swelling ratio experiments
The swelling ratio of bothhydrogel andCDS as a function of timewas
overviewed. It wasmeasured at predetermined time points including 1,
2, 6, 12, 24, 48, 72, 96 and 120 h after immersing samples in PBS. The
swelling ratios of hydrogel were found to be 108%, 112%, 128%, 136%,
150.5%, 166%, 177%, 177.6% and 178% at aforementioned intervals, re-
spectively, whereas the swelling ratios of CDS were ﬁgured out to be
105%, 110%, 117%, 120.5%, 124.5%, 127.6%, 133.7%, 134.5% and 135% at
predetermined intervals, respectively.d (ii) HA-JEF ED-600 hydrogel. Structural characterization of HA-JEF ED-600 hydrogel and
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In order to quantify the amount of both unreacted and single-end
anchorage JEF ED-600, ninhydrin assay was used. Ninhydrin assay
displayed that from the total amount of crosslinking agent (JEF ED-
600) utilized in the coupling reaction, 5.4% grafted through only one
amino group identiﬁed as single-end anchorage and 4.7% did not partic-
ipate in the coupling reaction and remained unreacted. Consequently,
the crosslinking efﬁciency determined based on the previously men-
tioned formula was equal to 89.9%.
3.4. Rheological characterization of HA-JEF ED-600 hydrogel
In order to assess the rheological properties of HA-JEF ED-600 hydro-
gel, stress-strain curve also called ﬂow curve was depicted by plotting
shear stress (Ʈ) against velocity gradient of the ﬂow or ﬂow rate (ϒ).
The relationship between Ʈ and ϒ is described based on Eq. (10), in
which “n” value refers to power law index. Fig. 2a exhibits log Ʈ against
log ϒ for both HA gel and HA-JEF ED-600 hydrogel, individually. Accord-
ingly, the “n” values for HA gel and HA-JEF ED-600 hydrogel gained from
the slopes of the latter plots were found to be 0.86 and 0.91, respectively.
Ʈ ¼ ηϒn ð10Þ
Fig. 2b and c represent the data acquired from SAOS analysis. Shear
storage or elastic (G′) and shear loss or viscous (G″) moduli were plot-
ted versus angular frequency for both HA gel prior to covalent
crosslinking reaction and HA-JEF ED-600 hydrogel. Obviously, for HA
gel G″ was higher than G′ within almost the whole range of analysis,
whereas for HA-JEF ED-600 hydrogel G′ was remarkably higher
than G″, indicating that the rheological behaviour of HA changed as
a result of crosslinking reaction. In the following, the phase shift tan-
gent described as tan δ = G″ / G′ was plotted versus angularFig. 2. Rheological measurements: (a) Stress-strain curve for HA and HA-JEF ED-600 hydroge
hydrogel. (d) Phase shift tangent vs. angular frequency for HA and HA-JEF ED-600 hydrogel.frequency for both HA gel and HA-JEF ED-600 hydrogel (Fig. 2d). It
was deduced that tanδ for HA-JEF ED-600 hydrogel was signiﬁcantly
lower than HA gel, stating that converting HA gel to HA-JEF ED-600
hydrogel led to signiﬁcant decrease in G″. As a consequence of hy-
drogel formation, the rheological properties of the matrix shifted
from a viscous (ﬂuid-like) behaviour to more elastic (solid-like)
material.
3.5. Preparation of Teriparatide loaded combination delivery system (CDS)
In order to clarify the effect of NPs:hydrogel ratios on the percentage
of NPs incorporation within the matrix of hydrogel, three different ra-
tios of NPs:hydrogel consisting of 1:1, 2:1 and 4:1 were evaluated dur-
ing the CDS preparation. The percentage of NPs incorporation was
ﬁgured out to be 86%, 46% and 26% for the aforementioned ratios, re-
spectively. On the other hand, the loading capacity of CDS was found
to be 2.31%, 2.4% and 2.5%, respectively.
3.6. Morphological characterizations
SEM images revealed that both HA-JEF ED-600 hydrogel (Fig. 3a)
and CDS containing Teriparatide (Fig. 3b) exhibited porous structure.
The only observable distinction between these two carriers lies in the
matrix surface. The matrix surface of hydrogel showed a relatively
smooth texture while the matrix surface of CDS is relatively rough due
to the NPs which are adhered to or are accommodated in the matrix
of hydrogel.
3.7. In vitro Teriparatide release studies
The release proﬁles of Teriparatide from PHBV/PLGA blend NPs, HA-
JEF ED-600 hydrogel, CDS and free Teriparatide are depicted in Fig. 4.
Due to the rapid release of free Teriparatide, which resulted in a 99.5%l. SAOS tests: G″ and G′modulus vs. angular frequency for (b) HA and (c) HA-JEF ED-600
Fig. 3. SEM images of (a) HA-JEF ED-600 hydrogel and (b) CDS consisting of PHBV/PLGA NPs loaded in HA-JEF ED-600 hydrogel. Arrows illustrate the loaded NPs.
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alysis bag on Teriparatide release was completely eliminated. The
release pattern of Teriparatide fromHA-JEF ED-600 hydrogel represent-
ed a relatively swift release resulted in 25% initial burst release within
12 h. 84.8% of total Teriparatide was released from HA-JEF ED-600 hy-
drogel within 10 days. The release proﬁle of Teriparatide from formerly
optimized PHBV/PLGA blend NPs was divided into two main phases. In
ﬁrst phase lasting for 5 days, 37.5% of total Teriparatide was released, of
this amount 22% was rapidly released in 12 h demonstrated the ﬁrstburst release and 15.5% was gradually released till the end of day 5. In
second phase lasting for 25 days, 26.9% of peptide was released, 11.5%
in second burst release and 15.4% in second plateau stage. Conversely
to PHBV/PLGA blend NPs, in newly constructed CDS the biphasic release
pattern vanished entirely. As it is shown in Fig. 4, 63% of total
Teriparatide was released from the newly designed CDS in a sustained
manner within 50 days. 57.4% of Teriparatide was released within
30 days and only 5.6% was released during the following 20 days in an
extremely gradual and sustained pattern. Only one burst release was
Fig. 4. In vitro cumulative release proﬁles of free Teriparatide, Teriparatide loaded hydrogel, Teriparatide loaded PHBV/PLGA NPs and Teriparatide loaded CDS (n = 3).
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in 12% burst release after 12 h, which was remarkably lower than the
burst releases observed in both NPs and hydrogels.3.8. Kinetic analysis of Teriparatide release from CDS
Different mathematical models were employed to elucidate the
mechanism of Teriparatide release from the fabricated CDS.
The obtained correlation coefﬁcients (R-squares) for the zero order,
ﬁrst order, Higuchi model and Korsmeyer-Peppas model were 0.76,
0.34, 0.78 and 0.99, respectively. The “n” value for the constructed CDS
was found to be 0.29.Fig. 5. Florescence spectroscopy of Teriparatide (….) and Teriparatide loaded CDS (―). The ﬂ
remained intact indicating structural stability.3.9. Intrinsic ﬂuorescence spectroscopy
The ﬂuorescence spectrum of Teriparatide loaded CDS in compari-
son with the intact Teriparatide was evaluated in order to corroborate
that Teriparatide was not exposed to structural alterations during for-
mulation (Fig. 5). Similar shapes of these two spectra revealed that no
changes occurred in the structure of Teriparatide during preparation
of CDS.
3.10. Circular dichroism
Circular dichroism spectroscopy in Far-UV region was performed to
ascertain that formulation processing and adding excipients did notuorophore groups in Teriparatide loaded CDS compared to pure Teriparatide have been
Fig. 6. Far-UV circular dichroism spectra of Teriparatide (―) and Teriparatide loaded CDS
(….). The secondary structure of Teriparatide loaded CDS is extremely similar to the neat
Teriparatide stating the structural stability.
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the solvent-subtracted Far-UV CD spectra of Teriparatide loaded CDS
and neat Teriparatide were extremely similar to each other. Thus, it
can be deduced that secondary structure of Teriparatide loaded CDS
remained intact during formulation.3.11. Effect of CDS and Teriparatide-CDS on viability of NIH3T3 cells
As it is shown in Fig. 7, MTT assay revealed that no remarkable toxic
effects could be ﬁgured out neither in CDS (drug free) nor in
Teriparatide loaded CDS in concentrations of 0.05, 0.5 and 5 nM, in com-
parisonwith control group, after 24 h.However, the cell viability in both
CDS (drug free) and Teriparatide loaded CDS treatment at concentration
of 50 nM, compared to control group, implies toxicity whereby the de-
gree of toxicity is more prominent in cells treated with Teriparatide
loaded CDS.
On the other hand, cells incubated for 48 h only showed toxicity at
50 nM of Teriparatide loaded CDS and no decrease in cell viability wasFig. 7. Cytotoxicity analysis of free and Teriparatide loaded CDS. NIH3T3 cells were treated
concentrations of CDS and Teriparatide (50 nM). The cell proliferation was determined us
*P b 0.05, ***P b 0.001 compared to control cells).observed in other groups. Interestingly, cell density was increased in
concentrations of CDS other than 50 nM, especially at 0.05 nM of both
CDS and Teriparatide loaded CDS.3.12. LD50 calculations
Common toxicity symptoms such as abnormal gait, dullness, lethar-
gy, hair shedding, burying the head in saw dust, salivation, arching and
rolling, lacrimation, chewing and lickingweremanifested in some treat-
ed animals. The mice, which exhibited laboured breathing and gasping,
eventually died within 3 days. Initially, at dose of 50 mg/kg no toxicity
symptoms were observed, whereas signs of poisoning were seen in
some animals in other doses. The number of dead mice, the percentage
of mortality, the corrected values for 0% and 100%mortality and probits
at each dose are tabulated in Table 1. In order to convert percentage of
mortality to probits, standard ﬁxed table previously introduced byMill-
er and Tainter for LD50 determinations was used (Table 2). As it is illus-
trated in Fig. 8, the log LD50 and LD50 were 2.12 and 131.8 mg/kg,
respectively.3.13. Serum calcium level determination
Mean serum calcium level for each group of animals was plotted
against time-points. In the control group, mean serum calcium level
remained relatively constant and no signiﬁcant alteration was detected
in all time-points. In group 2 injected by Teriparatide solution in PBS,
serum calcium level reached 10.9 mg/dl in day one, which was signiﬁ-
cantly higher than control group at the corresponding time (P-
value ≤ 0.05). Afterwards, calcium level fell in all time-points until it ﬁ-
nally reached 7.57 mg/dl. Serum calcium level exhibited a completely
different trend in group 3 injected by Teriparatide loaded CDS. In this
group, calcium level reached 10.23 mg/dl in day one, which was re-
markably higher than control group (P-value ≤ 0.05) but it represented
no signiﬁcant difference in comparison with group 2 (P-value ≥ 0.05).
Contrary to group 2, serum calcium level was increased in group 3 and
it reached 12.10 mg/dl at the end of day 50, which was signiﬁcantly
higher than both groups 1 and 2 at the similar time-point (P-
value ≤ 0.05) (Fig. 9). After 50 days, most of the CDS was degraded
and only partial residue of the fabricated CDS could be recovered from
the injection site in comparison with the ﬁrst day of injection.with different concentrations of Teriparatide loaded CDS (0.05–50 nM), corresponding
ing MTT assay at 24 h and 48 h after treatment (One way ANOVA, Dunnett's post test
Table 1
Results of the lethal doses of Teriparatide loaded CDS for the determination of LD50 after subcutaneous injection inmice. Five groups of mice (10 animals in each group) were injected by
ﬁve different doses of Teriparatide loaded CDS (50, 100, 200, 250 and 300 mg/kg) and toxic symptoms were monitored for up to 72 h after administration.
Group Dose (mg/kg) Log dose Dead %Dead %Corrected Probits
1 50 1.7 0 0 2.5 3.04
2 100 2.0 3 30 30 4.48
3 200 2.3 7 70 70 5.52
4 250 2.4 9 90 90 6.28
5 300 2.5 10 100 97.5 6.96
Table 2
Standard ﬁxed table for transformation of percentage mortalities to probits introduced by
Miller and Tainter.
Transformation
(%)
0 1 2 3 4 5 6 7 8 9
– 2.67 2.95 3.12 3.25 3.36 3.45 3.52 3.59 3.66
10 3.72 3.77 3.82 3.87 3.92 3.96 4.01 4.05 4.08 4.12
20 4.16 4.19 4.23 4.26 4.29 4.33 4.36 4.39 4.42 4.45
30 4.48 4.50 4.53 4.56 4.59 4.61 4.64 4.67 4.69 4.72
40 4.75 4.77 4.80 4.82 4.85 4.87 4.90 4.92 4.95 4.97
50 5.00 5.03 5.05 5.08 5.10 5.13 5.15 5.18 5.20 5.23
60 5.25 5.28 5.31 5.33 5.36 5.39 5.41 5.44 5.47 5.50
70 5.52 5.55 5.58 5.61 5.64 5.67 5.71 5.74 5.77 5.81
80 5.84 5.88 5.92 5.95 5.99 6.04 6.08 6.13 6.18 6.23
90 6.28 6.34 6.41 6.48 6.55 6.64 6.75 6.88 7.05 7.33
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In recent decades, various strategies have been employed to design
prolonged delivery systems for different peptides and proteins (Sinha
and Trehan, 2003; Fogueri and Singh, 2009;Malik et al., 2007; Jayamanti
et al., 2014). Nanoparticulate delivery systems and hydrogels have been
extensively studied for this purpose but they still have some problemat-
ic issues which restrict their widespread application. Undesirable burst
release, which could lead to adverse effects, is the principal obstacle for
most of these carriers loading with peptides and proteins (Zhang et al.,
2005). Nevertheless, NPs and hydrogels still represent favourable prop-
erties in designing prolonged delivery systems which cannot be dis-
guised (Segura et al., 2005; Ouasti et al., 2011; Leach and Schmidt,
2005; Gan and Wang, 2007; Estrada et al., 2014; Emami et al., 2014).
Thus, combining NPs and hydrogels to make a novel prolonged delivery
system has highly attracted pharmaceutical's attention in the recent
years. CDS has hopefully demonstrated favourable results in achieving
ideal controlled release systems for different therapeutic agents such
as dexamethasone, rifampicin and insulin (Bhardwaj et al., 2010; Hu
et al., 2012; Peng et al., 2012). In view of this, previously optimized
PHBV/PLGA blend NPs (Bahari Javan et al., 2016) were successfully em-
bedded in newly constructed HA-JEF ED-600 hydrogel.
Initially, HA-JEF ED-600 hydrogel was synthesized by reacting the
carboxylic groups on the backbone of HA formerly activated by EDC
and NHS, with amine groups on Jeffamine ED-600. FTIR and H NMR
ﬁndings ascertained the formation of amide bonds in chemically
crosslinked hydrogel. In order to assess the hydrogel behaviour, swell-
ing ratio, crosslinking efﬁciency and rheological characteristics of the
fabricated hydrogel were examined in advance to CDS preparation.
In general, swelling behaviour of hydrogels is known to be a critical
property which regulates the release of therapeutic agents (Hamidi
et al., 2008). In order to achieve equilibrium swelling ratio, the weight
of swollen hydrogel was examined at speciﬁc intervals. As soon as near-
ly constantweightwas obtained for swollen hydrogel, it was considered
as ameasure of equilibrium swelling ratio in PBS. Consequently, equilib-
rium swelling ratiowas found to be 177% after 3 days and it did not alter
signiﬁcantly after that and onlyminor swellingwas observed in thema-
trix of hydrogel. The data gained from in vitro release studies of
Teriparatide from HA-JEF ED-600 hydrogel further testiﬁed this result.
As HA-JEF ED-600 hydrogel swelled in PBS medium, the pore sizes of
hydrogel became slightly larger and subsequently the peptide release
was facilitated. In the ﬁrst 3 days of Teriparatide release from hydrogel,
53.4% of peptide was released, which was coincident with the signiﬁ-
cant swelling of hydrogel, while in the 7 days left, 31.4% of the remain-
ing Teriparatide was released, which was notably less than the amount
released within the ﬁrst 3 days. As the swelling of hydrogel started to
decrease after 3 days, Teriparatide release from hydrogel was also
diminished.
The swelling ratio of CDS was also determined in order to compare
the swelling ratio of CDS with hydrogel as well as investigate the effect
of NPs incorporation within the matrix of hydrogel on swelling behav-
iour. The swelling ratio of the fabricated CDSwas remarkably decreased
compared to hydrogel and it was found to be 135% after 5 days. Interest-
ingly, we found that introduction of PHBV/PLGA nanoparticles into the
matrix of hydrogel affected the swelling ratio, probably due to their in-
terferencewith the formation of crosslinking.Moreover, the structure ofCDS is more compact and dense compared to that of hydrogel alone,
which could restrict movement and relaxation, resulted in less swelling
(Hezaveh and Muhamad, 2012). The results are also in agreement with
a previous study inwhich it was illustrated that further incorporation of
Au nanospheres within thematrix of carrageenan hydrogels resulted in
additional strengthening of polymer network which restricted the
swelling of the nanocomposite (Salgueiro et al., 2013).
The extent of crosslinking efﬁciency of HA-JEF ED-600 hydrogel was
speciﬁed by subtracting single-end anchorage and unreacted amino
groups of JEF ED-600 from the total amount of JEF ED-600 initially
added as a bi-functional crosslinking agent to the medium of reaction.
For this purpose, ninhydrin assay extensively used in quantitative deter-
mination of α-amino acids was utilized. Brieﬂy, ninhydrin reacted with
freeα-amino groups and produced a purple blue dyewhichwas further
detected by UV spectrophotometer at 570 nm (Jeon et al., 2007).
Pursuant to ninhydrin assay, the percentage of unreacted JEF ED-600,
single-end HA-JEF ED-600 and the crosslinking efﬁciencywere estimat-
ed to be 4.7%, 5.4% and 89.9%, respectively. By summing single-end HA-
JEF ED-600 and the crosslinking efﬁciency values, the extent of conjuga-
tion percentage was found out to be 95.3%, which was further con-
ﬁrmed by H NMR area under curve. H NMR area under curve revealed
that HA-JEF ED-600 conjugation percentage, including both single-end
HA-JEF ED-600 and crosslinked HA-JEF ED-600, was 93.9%.The differ-
ence between these two values (1.4%) corresponded to the inevitable
errors of the two methods.
Both the stress-strain curve and the SAOS analysis were exerted to
evaluate the mechanical and viscoelastic properties of HA-JEF ED-600
hydrogel in comparison with HA gel. Stress-strain curve is identiﬁed
as a consequential graphical determination of material's mechanical be-
haviour (Kaur et al., 2012). The power law index, “n”, gained from
stress-strain curve is beneﬁcial to interpret a material ﬂow under a
small range of shear rate. If “n” value is smaller than one (n b 1), mate-
rial behaves as a shear thinning or pseudo plastic matrix in which the
viscosity decreases as a function of increasing in shear rate, but If “n”
value is greater than one (n N 1), material behaves as a shear thickening
or dilatancy matrix in which the viscosity increases as a function of in-
creasing in shear rate (Vorvolakos et al., 2011). In this work, the “n”
values for both HA gel and HA-JEF ED-600 hydrogel are smaller than
one (n b 1), thus it can be inferred that both HA gel and HA-JEF ED-
600 hydrogel show pseudo plastic behaviour even after crosslinking re-
action, although the pseudo plastic property of hydrogel was
Fig. 8. Plot of log-doses vs. probits from Table 1 for calculation of LD50 of Teriparatide loaded CDS administrated subcutaneously. LD50 of Teriparatide loaded CDSwas determined based on
Miller and Tainter method.
177N. Bahari Javan et al. / European Journal of Pharmaceutical Sciences 101 (2017) 167–181signiﬁcantly decreased in comparisonwith HA gel. The “n” value gained
for hydrogel was signiﬁcantly higher than the “n” value of HA gel. The
higher the “n” value, the less pseudo plastic behaviour will be obtained
which signiﬁes that the hydrogel exhibits more resistance to ﬂow and
shape alterations in comparisonwithHAgel and also decrease in viscos-
ity due to the employed stress occurs with more delay. SAOS analysis
demonstrates that HA gel treated as a viscous or ﬂuid-like material
based on the greater values achieved for G″ in comparison with G′ in al-
most all range of experiments (G″ N G′) but as the HA gel converted to
HA-JEF ED-600 hydrogel, the viscoelasticity altered towards a more
elastic or solid-like material and exceedingly greater values were ob-
tained for G′ compared to G″ (G′ N G″) (Mayol et al., 2008; Kim et al.,
2007). Afterwards, phase shift (δ) corresponded to tanδ= G″/G′ was
plotted against angular frequency. Phase shift is an indicator to display
the behaviour of material between purely viscous (δ=90°) and purely
elastic (δ= 0°) condition (Kreger and Voytik-Harbin, 2009). Since tanδ
in the constructed hydrogel is manifestly lower than the gel, the former
results about shifting the viscoelasticity from viscous or ﬂuid-like mate-
rial in HA gel to elastic or solid-like material in hydrogel were re-
substantiated. In general, hydrogels with greater values of G′, common-
ly exhibitmore resistance against deformation, possess longer retentionFig. 9. Serum calcium level vs. time inmicewithin 50 days after subcutaneous injection of blank
30, 40 and 50 days after injection, three mice in each group were anesthetized and serum ca
method. The animals injected by Teriparatide loaded CDS had signiﬁcantly higher (*P b 0.05) stime after application and they are ﬁrmer and harder than hydrogels
with lower G′. The results are in accordance with a previous study in
which Tommaso Iannitti et al. claimed that Varrioﬁl as a crosslinked
hyaluronan hydrogel possessed elastic modulus higher than viscous
modulus resulting in more resistance to shape alterations, better
volumizing effect in the soft tissues and long-lasting retention
(Iannitti et al., 2013). In a recent study, tyramine modiﬁed hyaluronic
acid (HA–Tyr) hydrogels with different degrees of substitution were
prepared and thereafter rheological measurements revealed that elastic
moduluswas signiﬁcantly higher than viscousmodulus in all specimens
(Loebel et al., 2015). Additionally, in amide derivatives of HAwith linear
alkyl-amines previously synthesized byMauro Pavan et al. themechan-
ical properties of conjugates were shifted towards more elastic mate-
rials after chain polymerization (Pavan et al., 2013).
In order to prepare CDS, NPs incorporation within the matrix of hy-
drogel fell out concurrently to the crosslinking procedure. CDS structure
imaged by SEM displayed a porous structure in which NPs either ad-
hered to or incorporated within the matrix of hydrogel, whereas there
was no sign of NPs in the structure of HA-JEF ED-600 hydrogel. Thus,
the discrepancy between the structure of CDS and hydrogel was con-
ﬁrmed by SEM topographies.CDS, free Teriparatide (0.5 mg/kg) and Teriparatide loaded CDS (0.5mg/kg). At 0, 1, 7, 15,
lcium levels were determined by colorimetric assay with o-cresolphthalein complexone
erum calcium level than the other groups after 50 days.
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NPs:hydrogel ratio did not show signiﬁcant enhancement in %LC of
CDS. Additionally, increment in the ratio of NPs:hydrogel led to an
unfavourable high decrease in the percentage of NPs incorporation.
These results are in favour of this hypothesize that hydrogel structure
is likely to have limited capacity for accommodating NPs within its ma-
trix. Thus, the amount of NPs whichwould be able to incorporate in the
hydrogel is restricted by limited capacity of hydrogel and afterwards by
the employed method for fabricating CDS. Since embedding the NPs
within the matrix of hydrogel and crosslinking reaction occur simulta-
neously, it might be a deterrent factor for more incorporation of NPs.
As a result, some NPs remained un-entrapped during the preparation
of CDS and even increasing in the ratio of NPs:hydrogel did not illustrate
favourable results. Finally, it was derived that increasing in
NPs:hydrogel ratio is a vain attempt which does not produce any desir-
able results in improving the percentage of NPs incorporation and %LC
of CDS. Hence, ratio 1:1 of NPs:hydrogel was chosen to be the best
ratio for CDS preparation.
In the current study, the release proﬁle of Teriparatide fromCDSwas
compared with both HA-JEF ED-600 hydrogel and PHBV/PLGA NPs. The
release proﬁle of Teriparatide fromHA-JEF ED-600 hydrogel exhibited a
swift initial release, which might be due to the amount of Teriparatide
adsorbed on the surface of hydrogel, thus led to faster release. Addition-
ally, the concentration gradient of peptide created inside and outside of
the hydrogel might be responsible for the latter phenomenon caused
Teriparatide located in the superﬁcial part of the hydrogel to be spread
out of the hydrogel swiftly. Totally 84.8% of Teriparatide was released
from hydrogel within 10 days in an uncontrolled manner implying
that the hydrogel alone was not able to thoroughly retard the peptide
release over a long period of time. The results are well in consistency
with those found for Erythropoietin loaded HA hydrogels, in which
25% burst release was distinguished in the release proﬁle continued by
90% Erythropoietin release within 10 days (Hahn et al., 2006). In anoth-
er study conducted by Fan Lee et al., 25.8% of α-amylase from HA-
tyramine hydrogel was released within only 2 h (Lee et al., 2009). In
spite of favourable properties of hydrogels for delivery of peptides and
proteins such as low tendency for protein aggregations and denatur-
ation (Hamidi et al., 2008), desirable controlled release proﬁle is not
fully achieved with these carriers. The same obstacle also exists in the
release proﬁle obtained from nanoparticulate systems. In PHBV/PLGA
blend NPs, the ﬁrst and second burst releases were ascribed to the ad-
hered drug on the surface shell of NPs and the rapid degradation of
PLGA in comparison with PHBV, respectively (Bahari Javan et al.,
2016). Although fabricating core-shell like NPs reduced the sudden
burst release due to the presence of shell around the NPs, relatively
large amount of therapeutic agent which still remained on the surface
of NPs led to uncontrolled burst release (Zhu et al., 2009). In contrast
to HA-JEF ED-600 hydrogel and PHBV/PLGANPs, the initial burst release
substantially decreased from 25% in hydrogel and 22% in NPs to 12% in
the CDS, indicating the pivotal role of CDS in diminishing the undesir-
able burst release. Besides this, the second burst release observed in
PHBV/PLGA NPs apparently disappeared in CDS. Pursuant to the obtain-
ed results in this work, it seems that dispersing NPswithin thematrix of
hydrogel represents promising results in both lessening unfavourable
burst release generally seen in controlled delivery systems and
prolonging peptide release. Evidence based results conﬁrmed this
claim. 64.4% of Teriparatide was released from NPs within 30 days
whereas 63% (relatively the same amount) of peptide was released
fromCDSwithin 50 days. Thus, themore retarding effect of CDS in com-
parison with NPs was testiﬁed. It is hypothesized that after swelling of
hydrogel, PHBV/PLGA NPs started to be released from the matrix of
CDS. As the swelling of hydrogel increased over time, the more NPs
got released from the CDS. Afterwards, the surrounding aqueous medi-
um penetrated into the matrix of NPs and Teriparatide was released
based on diffusion mechanism. The slower Teriparatide release from
day 30 to 50 might be due to the formation of intermolecular linkagesin PHBV/PLGA NPs which could postpone Teriparatide release. More-
over, the acquired ﬁndings in the present study are in agreement with
the previous studies, in which HA hydrogels containing vascular endo-
thelial growth factor (VEGF) loaded PLGA microspheres were recog-
nized as a potential carrier for controlled delivery of biofactors (Wang
et al., 2011).
Two mechanisms might be involved in partial and incomplete re-
lease of Teriparatide from NPs.
Firstly, Teriparatide molecules might unfavourably be entrapped
within the long polymeric chains of PHBV and never become exposed
to be released. Since PHBV has a higher molecular weight and longer
polymeric chains than PLGA, Teriparatide entrapment within the poly-
meric chains of PHBV is more probable. This phenomenon could also
be attributed to the interactions between Teriparatide and copolymers
during NPs preparation. Undesirable interactions between some
amounts of Teriparatide and copolymers might decrease the amounts
of drug accessible for release. These interactions (mainly van der
Waals and partially chemical interactions)might be additional inhibito-
ry factors in releasing some amounts of Teriparatide. Chemical and van
der Waals interactions have been previously introduced as the reasons
of partial release of various therapeutic agents (Ukmar et al., 2011b;
Ukmar et al., 2011a; Peng et al., 2013).
Secondly, stronger hydrophobicity and slower degradability of PHBV
in comparison to PLGA might have been a delaying factor for facile dif-
fusion of aqueous medium to the matrix of copolymer causing rigidity
in the skeleton of NPs. As a result, bulk degradation and subsequent
pores formation occurred slowly, which might have been the reasons
for the intensiﬁcation of Teriparatide entrapment within the intermo-
lecular linkages of copolymer during diffusion. Insufﬁcient pores in the
structure of NPs might be an inhibitory factor in drug release.
Our ﬁndings disclosed that the swelling ratio of CDS (Teriparatide
NPs loaded in hydrogel) was decreased by incorporating NPs within
the matrix of hydrogel compared to blank hydrogel. As a result, CDS
retained some amounts of NPs. It is also hypothesized that NH2 groups
in HA- JEF ED 600 hydrogel might be adsorbed by the surface of the
PHBV/PLGA NPs and cause interaction between NPs and hydrogel,
thereby resulting in retained effect. Hence, the fabricated CDS could
not release all the amounts (100%) of the NPs initially incorporated
within the matrix of hydrogel probably due to two reasons, ﬁrstly less
swelling ratio of CDS compared to blank hydrogel and secondly interac-
tions between NPs and hydrogel. The retaining effect of CDS on NPs re-
lease might lead to reach the relatively same percentage of release in
longer time (63% release from CDS in 50 days vs. 64.4% release from
NPs within 30 days).
After NPs release from the matrix of hydrogel, the limiting factors
previously discussed such as Teriparatide entrapmentwithin both poly-
meric chains and intermolecular linkages and drug interactionswith co-
polymers, resulted in Teriparatide partial release from NPs. The
retaining effect of CDS on NPs could not be disguised in manifestation
of incomplete release, since it has been extensively studied in previous
researches. Peng and colleagues demonstrated that only 19.11% of insu-
lin was released from PHBHHx (poly (3-hydroxybutyrate-co-3-
hydroxyhexanoate)) nanoparticles loaded chitosan hydrogel within
31 days. Peng et al. proposed that drug release was dually impeded by
both NPs and hydrogel and eventually led to incomplete release. They
introduced strong hydrophobicity and slow degradability of PHBV as
the rate limiting factors in insulin release (Peng et al., 2013). Stanwick
and colleagues fabricated a composite drug delivery system consisting
of PLGA NPs dispersed in an injectable methyl cellulose hyaluronan hy-
drogel for controlled delivery of Neurotrophin-3 (NT-3). They assumed
that the interaction between PLGANPs and hyaluronan hydrogel result-
ed in plateau phase in release proﬁle of NT-3 aswell as in an incomplete
release. They also indicated that methyl cellulose in hyaluronan hydro-
gel adsorbed to the surface of PLGA NPs which led to about 65% release
within 30 days (Stanwick et al., 2012). In another study conducted by Li
et al., honokiol release from composite drug delivery system consisting
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35% release in 15 days. They assumed that honokiol release from com-
posite was concentration dependent and higher drug loading resulted
in less release (Li et al., 2009). E. Tous et al. showed that there was no
difference in the rate of drug release between the gel only and the com-
posite drug delivery system (PLGA microspheres loaded in hyaluronic
acid based hydrogel) (Tous et al., 2012).
The data acquired from in vitro release studies were ﬁtted to differ-
ent mathematical models to anticipate the mechanism of Teriparatide
release fromCDS. In this study, the bestﬁttingmodel for Teriparatide re-
lease was Korsmeyer Peppas model since the highest R-square value
(r2 = 0.99) was achieved with this model stating the favourable linear-
ity of themodel. In General, the diffusional exponent, “n”, in Korsmeyer
Pappas model is utilized to clarify the conquering mechanism involving
in drug release from a carrier. Universally, the drug transport is catego-
rized as Fickian diffusion (n = 0.5), Quasi-Fickian diffusion (n b 0.5),
Case II transport (n = 1), Non-Fickian or anomalous transport
(0.5 b n b 1) and Super Case II transport (n N 1), according to the “n”
power. In this experiment, it was ﬁgured out that the “n” value was
0.29 (n b 0.5). As a result, Quasi-Fickian diffusion could be the funda-
mental mechanism of Teriparatide release from CDS. The results are in
accordance with former reports in which “n” value lower than 0.5 was
considered as an indicator for Quasi-Fickian diffusion mechanism
(Halder et al., 2012; Lao et al., 2011; El-Leithy et al., 2010).
Intrinsic ﬂuorescence and circular dichroism spectroscopy were
employed to afﬁrm that Teriparatide structure remained intact
during formulation and elevated temperature, organic solvents
and that the addition of various excipients had no destructive ef-
fects on peptide (Johnson, 1990; Capelle et al., 2007; Shoyele
et al., 2011). The ﬂuorescence spectroscopy provides evidence to
prove that the location of the ﬂuorophore groups consisting of
tryptophan and phenylalanine in the structure of Teriparatide re-
mains preserved during formulation. In this technique, any degree
of either red-shift (left shift) or blue-shift (right shift) in the spec-
tra of peptides and proteins could be a proof of undesirable struc-
tural alterations in these compounds (Vivian and Callis, 2001). In
the current study, no changes in ﬂorescence intensity were
discerned and neither right shift nor left shift was distinguished
in the two spectra, hence the location of ﬂuorophore amino acids
in the structure of Teriparatide were maintained during formula-
tion. These results were further conﬁrmed by CD spectroscopy.
CD spectroscopy is known as a valuable technique which provides
useful information about the secondary structure of different pep-
tides (Zull et al., 1990). The Far-UV CD spectra of both neat
Teriparatide and Teriparatide loaded CDS were comparable to
each other stating that secondary structure of Teriparatide was
not altered during the formulation process.
According to MTT assay results, the fabricated CDS not only in drug
free form but also in drug loaded form, displayed no cytotoxic effects
on NIH3T3 cell line in concentrations of 0.05, 0.5 and 5 nm after 24 h.
The obtained results are well in consistency with a previous study in
which PTH (1–34) loaded PLGAmicrospheres exhibited no cytotoxic ef-
fects on MC3T3-E1 cell line after 24 h (Eswaramoorthy et al., 2012). In
another study, the cytotoxicity of PTH (1–34) loaded chitosan NPs
were evaluated using Saos-2, UMR 106, L 929, and NIH3T3 cell lines
and it was concluded that relative cell viability was unaffected by the
fabricated nanoformulation after 24 h (Narayanan et al., 2012). In the
current study, the signiﬁcant toxicity observed for both CDS (drug
free) and Teriparatide loaded CDS in concentration of 50 nM in compar-
ison with control group is not controversial and it does not cause any
concern for application in clinics since this concentration is approxi-
mately 107 times higher than physiologic concentration of Teriparatide.
After 48 h, decline in the number of viable cells was only detected in
Teriparatide loaded CDS at concentration of 50 nM compared to the
control group. The cell viability of both CDS (drug free) and Teriparatide
loaded CDS in all concentrations, except for 50 nM CDS, wassigniﬁcantly increased compared to the control group. Since
Teriparatide alone did not disclose signiﬁcance increase in the number
of viable cells after 48 h, it seems that the rise in cell viability seen in
other groups is related to the constructed CDS. It can be hypothesized
that the fabricated CDS forms a scaffold like structure which resembles
3D cell cultures platforms and mimics the native extracellular matrix
(Tibbitt and Anseth, 2009).
The LD50 test was initially developed in 1927 and it is now part of all
governmental guidelineswhich adjust andmanage toxicological assess-
ments of various compounds (Zbinden and Flury-Roversi, 1981).
Knowledge of LD50 is also known as a valuable tool to measure the
acute toxicity of substances (Arome and Chinedu, 2013). In the present
study, LD50 value of Teriparatide loaded CDS was achieved based on
Miller and Tainter method (Miller and Tainter, 1944; Randhawa,
2009). In order to measure the LD50 of Teriparatide after loading in
CDS and evaluate whether the constructed CDS could affect the LD50
of Teriparatide, LD50 determinationwas conducted. LD50 value achieved
was 131.8 mg/kg for Teriparatide loaded CDS and it was conﬁrmed that
loading Teriparatide in the newly fabricated CDS did not affect the LD50
of neat Teriparatide.
Besides achieving favourable release proﬁle, the principal challenge
of peptide delivery is to preserve the bioactivity of the peptide after ad-
ministration (Brown, 2005). Fabricating a controlled release formula-
tion without evaluating its bioactivity and effectiveness in in vivo is a
vain attempt. Teriparatide is the primary regulator of calcium homeo-
stasis in bone and kidney. Itmainly acts through renal tubular reabsorp-
tion of calcium and intestinal calcium absorption (Brown and Juppner,
2006). Hence, serum calcium level measurement could give useful in-
formation about the effective delivery of Teriparatide. Results gained
in the present study reveal that serum calcium level was immediately
increased after subcutaneous injection of Teriparatide alone in compar-
isonwith the control group. But it started to fall down after day 1.This is
probably due to the short half-life and rapid metabolic degradation of
Teriparatide (Wei et al., 2004). These two reasonsmight makemultiple
injections of Teriparatide unavoidable tomaintain its effectiveness. Sim-
ilar to Teriparatide alone, we inferred that serum calcium level was in-
creased after administration of Teriparatide loaded CDS indicating that
the biological activity of Teriparatide had been maintained. Further-
more, serum calcium level was signiﬁcantly elevated in all time-points
during delivery of the peptide stating that the constructed Teriparatide
loaded CDS could act effectively. Eventually, we deduced that
Teriparatide alone should be administrated frequently to maintain the
appropriate serum calcium level since calcium concentration returned
to baseline level promptly after injection of Teriparatide. But serum cal-
cium level followed an ascending trend after administration of
Teriparatide loaded CDS and it reached an approximately constant
level after 50 days. Therefore, there was no need for daily injection.
Most importantly, designing such an effective prolonged release formu-
lation of Teriparatide will enhance patient's compliance by reducing the
problems and discomfort of frequent injections, which is the valuable
achievement of this study.
The remnants of CDS after 50 days was ascribed to a combination of
the impact of local tissue response on degradation and the suspected
hydrophobic interactions as previously discussed by E. Tous et al. Simi-
lar to our work, they represented that nanocomposite containing PLGA
microspheres embedded in hyaluronic acid hydrogel had remnants of
hydrogel composite present between inﬁltrated tissues after 4 weeks
(Tous et al., 2012). Additionally, the site of injection was monitored
for symptoms of undesirable adverse effects after subcutaneous admin-
istration in mice and no sign of redness or swelling at the injection site
was identiﬁed during 50 days.
5. Conclusion
A novel CDS consisting of PHBV/PLGA NPs loaded in HA-JEF ED-
600 hydrogel with the aim of preparing injectable formulation for
180 N. Bahari Javan et al. / European Journal of Pharmaceutical Sciences 101 (2017) 167–181prolonged delivery of Teriparatide was successfully designed and
characterized. Swelling behaviour, crosslinking efﬁciency and rhe-
ological properties were all conﬁrmative indicators for converting
HA gel to HA-JEF ED-600 hydrogel. Morphological assessments of
CDS revealed that the incorporation of NPs within the matrix of
hydrogel took place. The more prolonging effect of CDS on
Teriparatide release in comparison with NPs and hydrogel was
proven by the obtained results. Intrinsic ﬂorescence and circular
dichroism spectroscopy were all in favour of keeping the structural
stability of Teriparatide after formulation. The toxicity of CDS was
ruled out based on MTT assay results. The elevation trend of
serum calcium level acquired after administration of Teriparatide
loaded CDS in mice demonstrated that this drug delivery system
could be effective in in vivo and the bioactivity of Teriparatide
was preserved. In addition, the application of biocompatible, bio-
degradable, non-toxic and non-irritant polymers will hopefully
make this novel delivery system safe and one step closer to clinical
use.
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